Revvity (NYSE:RVTY) reported fourth-quarter and full-year 2025 results on Monday that exceeded Wall Street estimates, bolstered by resilient demand across its life sciences and diagnostics portfolios.
The Waltham, Massachusetts-based company also issued an optimistic outlook for 2026, projecting continued expansion in its high-margin software and AI-augmented drug discovery platforms.
For the quarter ended Dec. 28, 2025, Revvity posted net income of $112 million, or 87 cents per share.
When adjusted for one-time items, earnings reached $1.70 per share, significantly outpacing the $1.58 average analyst estimate.
Revenue for the period rose 6% to $772 million, driven by organic growth in immunodiagnostics and the integration of new scientific software solutions.
The full-year performance underscored Revvity’s transition into a specialized health science firm.
While GAAP earnings for 2025 were $2.07 per share, adjusted earnings reached $5.06, topping the upper end of the company’s previous guidance.
Annual revenue grew to $2.86 billion, reflecting a 4% increase as the firm successfully navigated a challenging macroeconomic environment for early-stage biotech funding.
Looking forward, Revvity initiated full-year 2026 guidance, forecasting revenue between $2.96 billion and $2.99 billion.
The company also expects adjusted earnings for the coming year to range from $5.35 to $5.45 per share, representing high-single-digit growth as it aims for adjusted operating margins of approximately 28%.